30-Second Takeaway
- Dynamic neurologic and temperature trajectories refine prognostication after TBI and ECPR-managed arrest.
- Prehospital and ICU risk scores quantify short-term mortality, informing triage and code status discussions.
- Antibiotic de-escalation in sepsis appears safe and reduces exposure and length of stay.
- Functional imaging and systems infrastructure meaningfully influence TBI outcomes and resource planning.
- Use of adjuncts like IV vitamin C in sepsis remains rare and highly evidence-sensitive.
Week ending December 27, 2025
Neuroprognostication, sepsis stewardship, and prehospital risk tools shaping modern trauma critical care
Temperature variability after rewarming predicts outcomes in ECPR-treated OHCA
In this six-ICU cohort of ECPR-treated out-of-hospital arrest patients under standardized TTM, 48–72-hour post-rewarming temperature trajectories stratified prognosis. A high temperature variability pattern was associated with substantially lower 90-day mortality than low variability (34.6% vs 53.5%). The high-variability group also had fewer poor neurological outcomes and less moderate or severe bleeding. Findings were prospectively validated, suggesting that post-rewarming temperature variability may be a useful prognostic marker, not necessarily a modifiable target.
Dynamic GCS trajectories outperform single scores for predicting TBI mortality
This multicenter ICU study of 3,132 adults with TBI used serial GCS values over 120 hours to derive four neurologic trajectories. Persistently Low GCS trajectories carried the highest adjusted mortality risk (HR 4.95 vs Stable High). A time-based GCS area-under-the-curve metric independently correlated with mortality, strongest at threshold 13. Adding trajectory class to baseline models improved discrimination (AUC 0.82 to 0.86), suggesting serial GCS trends meaningfully refine prognosis. These tools may support family counseling and trial stratification, but require prospective implementation studies before driving withdrawal decisions.
Day-4 antibiotic de-escalation in sepsis appears safe and shortens treatment
This target trial emulation included 36,924 adults with community-onset sepsis started on broad-spectrum antibiotics without multidrug-resistant pathogens. De-escalation of anti-MRSA or anti-Pseudomonas agents on day 4 yielded similar 90-day mortality to continuation (OR ~1.0). De-escalation reduced antibiotic days to day 14 and shortened hospitalization across both anti-MRSA and anti-Pseudomonas cohorts. Other secondary outcomes were similar, despite more than twofold variability in de-escalation rates across 67 hospitals. Results support structured day-3–4 reassessment and guideline-driven narrowing in clinically stable sepsis without resistant organisms.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.